Alnylam Pharmaceuticals
ALNY
#564
Rank
S$55.77 B
Marketcap
S$420.54
Share price
0.51%
Change (1 day)
31.59%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Earnings for Alnylam Pharmaceuticals (ALNY)

Earnings in 2024: -S$0.3 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company's current earnings are S$3.21 Billion. In 2024 the company made an earning of -S$0.3 Billion, an increase over its 2023 earnings that were of -S$0.4 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Alnylam Pharmaceuticals from 2003 to 2024

Annual earnings

Year Earnings Change
2024-S$0.3 Billion-24.59%
2023-S$0.4 Billion-67.84%
2022-S$1.23 Billion36.93%
2021-S$0.9 Billion-8.04%
2020-S$0.98 Billion-15.66%
2019-S$1.16 Billion12.23%
2018-S$1.03 Billion62.91%
2017-S$0.64 Billion17.78%
2016-S$0.54 Billion43.44%
2015-S$0.38 Billion60.69%
2014-S$0.24 Billion98.2%
2013-S$0.12 Billion
2011-S$69.25 Million27.48%
2010-S$54.32 Million-10.92%
2009-S$60.98 Million95.77%
2008-S$31.15 Million
2006-S$49.9 Million-9.13%
2005-S$54.92 Million34.74%
2004-S$40.76 Million36.79%
2003-S$29.8 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Novartis
NVS
S$20.65 B 12,447.77%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
S$11.49 B 6,883.12%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
S$6.60 B 3,913.80%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
-S$0.32 Billion-293.52%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
-S$59.92 Million-136.39%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
-S$0.21 Billion-222.38%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
S$2.71 B 1,551.35%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
S$0.17 B 8.12%๐Ÿ‡บ๐Ÿ‡ธ USA